Stockscreener 앱 받기
0.3385
1.23%
0.0041
Elevation Oncology Inc 주식(ELEV)의 최신 뉴스
JPMorgan Chase & Co. Purchases 119,041 Shares of Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Geode Capital Management LLC Grows Stock Holdings in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Renaissance Technologies LLC Sells 182,673 Shares of Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
William Blair Reaffirms Their Buy Rating on Elevation Oncology (ELEV) - The Globe and Mail
Elevation Oncology Inc Inc. (ELEV) Price Performance: The Role of Share Buybacks and Stock Splits - investchronicle.com
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
Elevation Oncology Inc (ELEV)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - DWinneX
Elevation Oncology Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Elevation Oncology reveals promising ADC data for solid tumors - Investing.com
Elevation Oncology reveals promising ADC data for solid tumors By Investing.com - Investing.com India
Breakthrough Cancer Drug EO-1022 Outperforms Existing HER3 Therapies in Stability and Anti-Tumor Activity - Stock Titan
Adversity is less terrifying than hope: Elevation Oncology Inc (ELEV) - Sete News
Elevation Oncology (ELEV) to Release Quarterly Earnings on Thursday - Defense World
Market Recap Check: Elevation Oncology Inc (ELEV)’s Negative Finish at 0.37, Up/Down -1.61 - DWinneX
Potential Price Increase for Elevation Oncology Inc (ELEV) After Recent Insider Activity - knoxdaily.com
Are Elevation Oncology Inc’shares a good deal? - uspostnews.com
Elevation Oncology Inc (ELEV): What Makes The Stock Good? - Marketing Sentinel
GSK prepares to relaunch Blenrep; Activists challenge another ‘zombie’ biotech - BioPharma Dive
Elevation mulls strategic alternatives, including closure, amid activist pressure - PharmaLive
Elevation Oncology (ELEV) Gets a Hold from Leerink Partners - The Globe and Mail
Finance Watch: Investors Push ESSA Pharma, Elevation Oncology To Wind Down - insights.citeline.com
Analysts Set Elevation Oncology, Inc. (NASDAQ:ELEV) PT at $3.39 - Defense World
Rare NRG1 Fusion Market to Reach New Heights in Growth by 2034, - openPR.com
Fierce Biotech Layoff Tracker 2025: Pfizer sells site, cuts staff; Opthea reduces workforce by 65% - Fierce Biotech
Trading Day Review: Elevation Oncology Inc (ELEV) Loses Momentum, Closing at 0.25 - DWinneX
Elevation Oncology opts for early term loan repayment By Investing.com - Investing.com South Africa
Elevation Oncology opts for early term loan repayment - Investing.com
Elevation Oncology IncTo Prepay Term Loan Under Loan & Security Agreement Dated July 27, 2022SEC Filing - MarketScreener
Elevation Oncology stock hits 52-week low at $0.24 By Investing.com - Investing.com Canada
Virtu Financial LLC Takes $36,000 Position in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Elevation Oncology’s Chief Medical Officer Steps Down - TipRanks
What is Elevation Oncology Inc (ELEV) Stock Return on Shareholders’ Capital? - Sete News
A closer look at Elevation Oncology Inc (ELEV)’s stock price trends - uspostnews.com
Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025 - Longview News-Journal
Elevation Oncology (NASDAQ:ELEV) Given “Equal Weight” Rating at Stephens - Defense World
Analysts Set Expectations for ELEV FY2029 Earnings - Defense World
Elevation Oncology (NASDAQ:ELEV) Cut to “Neutral” at Piper Sandler - The AM Reporter
Massachusetts-Based Elevation Oncology Cuts 70% of Workforce After Drug Setback - NewsBreak: Local News & Alerts
Elevation Oncology (NASDAQ:ELEV) Rating Lowered to “Market Perform” at Citizens Jmp - Defense World
Elevation Oncology (NASDAQ:ELEV) Rating Lowered to Neutral at Piper Sandler - Defense World
Elevation Oncology (NASDAQ:ELEV) Rating Lowered to Market Perform at Leerink Partners - Defense World
HC Wainwright Lowers Elevation Oncology (NASDAQ:ELEV) Price Target to $1.00 - Defense World
Elevation Oncology (NASDAQ:ELEV) Cut to “Hold” at Leerink Partnrs - Defense World
Elevation Oncology (NASDAQ:ELEV) Cut to Hold at Wedbush - Defense World
Elevation Oncology, Inc. (NASDAQ:ELEV) Receives $6.83 Average Target Price from Analysts - Defense World
Elevation Oncology Plunges 42% on Ending Development of Lead Drug - MSN
Elevation Oncology stock rating cut amid ADC asset halt By Investing.com - Investing.com Canada
Elevation Oncology Plunges 42% On Ending Development Of Lead Drug - Barchart
5.24%
자본화:
|
볼륨(24시간):